US Markets in:   hrs   min   sec

Set StockTrendNews.com as your Homepage! - Click Here Home     About Us     Subscribe     Contact
 
StockTrendNews (STN) Exclusive: Keryx Biopharmaceuticals, Inc.
Enter Symbol or Keywords
x
Latest 12 months Revenue for Keryx Biopharmaceuticals is Up 1079.26% according to T12-NEWS   Stock Quote: (NCM:KERX)
11/18/2009  
2.31 0.00 0.00% 0
Latest 12 months Revenue for Keryx Biopharmaceuticals is Up 1079.26% according to T12-NEWS  
Last Price Change % Chg Volume
New York, NY, November 18, 2009,T12-NEWS says that trailing twelve month (TTM) Revenue for Keryx Biopharmaceuticals (NASDAQ:KERX) for its twelve months ended September 30, 2009 increased by 1079.26% t ... read full story  
Website Address: www.keryx.com
Industry: Bio-Pharma & Therapeutics
Most Recent STN Exclusives
x
02/09/2010
Cash Flow from Operations Improves 82% for News Corp.
02/09/2010
Revenue for Coach Increases by 3.25% even though Revenue for Apparel Industry Decreases by -22.4% over Latest 12 Months
02/09/2010
Free Cash Flow for News Corp. Reaches Two Year High
02/09/2010
Cash Flow from Operations Turns Positive for Siemens' First Quarter
02/09/2010
StockDiagnostics.com Has Issued a Cashless Earnings Warning For Energy XXI
02/08/2010
Second Quarter EBITDA Turns Positive for Harris
02/08/2010
Twelve Year High in EBITDA for Amazon.com
02/08/2010
Cash Flow from Operations for McCormick Reaches Fifteen Year High
02/08/2010
EBITDA for BMC Software Reaches Thirteen Year High
02/08/2010
EBITDA for CA Reaches Nine Year High
Interactive Chart: KERX
x
More STN Exclusives for: KERX
x
11/20/2009
Twelve Months EBITDA Turns Positive for Keryx Biopharmaceuticals
11/18/2009
Latest 12 months Revenue for Keryx Biopharmaceuticals is Up 1079.26% according to T12-NEWS
11/18/2009
OPS Ranking Upgrade for Keryx Biopharmaceuticals
... more KERX exclusives
Other News Sources: KERX
x
02/05/2010
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
02/03/2010
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
02/02/2010
Keryx Biopharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
... more KERX news from other sources
Daily Market Updates
x
02/09/2010
Markets Close Day After Strong Rally as Concerns Ease re Greece
Stocks closed today's strong rally following speculation that the European Union will step in to bail out Greece. Germany and its European Union partners are expected to offer Greece and other troubled EU members loan guarantees. Oil climbed almost $ ... read full story

30 Day Free Trial - MarketWatch Retirement Weekly

Free 30 Day Trial -MarketWatch Hulbert Interactive

Visit Tradesight



Sponsored Links
Attend a Free Webinar on How to Trade Stocks
InvestView.com
Increase Your Stock Market Performance by Using the News Management Interface that the Pros Use
Knobias.com

 
 
 
x


 
x
     
 
©2010 StockTrendNews.com
Disclaimer Terms of Sales Privacy About Us